开发具有先进靶向功能的信使核糖核酸纳米药物。

Developing mRNA Nanomedicines with Advanced Targeting Functions.

作者信息

Wang Ji, Cai Lijun, Li Ning, Luo Zhiqiang, Ren Haozhen, Zhang Bing, Zhao Yuanjin

机构信息

Department of Radiology, Nanjing Drum Tower Hospital, Medical School, Nanjing University, Nanjing, 210008, People's Republic of China.

State Key Laboratory of Bioelectronics, School of Biological Science and Medical Engineering, Southeast University, Nanjing, 210096, People's Republic of China.

出版信息

Nanomicro Lett. 2025 Feb 21;17(1):155. doi: 10.1007/s40820-025-01665-9.

DOI:10.1007/s40820-025-01665-9

PMID:39979495

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11842722/

Abstract

The emerging messenger RNA (mRNA) nanomedicines have sprung up for disease treatment. Developing targeted mRNA nanomedicines has become a thrilling research hotspot in recent years, as they can be precisely delivered to specific organs or tissues to enhance efficiency and avoid side effects. Herein, we give a comprehensive review on the latest research progress of mRNA nanomedicines with targeting functions. mRNA and its carriers are first described in detail. Then, mechanisms of passive targeting, endogenous targeting, and active targeting are outlined, with a focus on various biological barriers that mRNA may encounter during in vivo delivery. Next, emphasis is placed on summarizing mRNA-based organ-targeting strategies. Lastly, the advantages and challenges of mRNA nanomedicines in clinical translation are mentioned. This review is expected to inspire researchers in this field and drive further development of mRNA targeting technology.

摘要

新兴的信使核糖核酸（mRNA）纳米药物已如雨后春笋般涌现用于疾病治疗。近年来，开发靶向mRNA纳米药物已成为一个令人兴奋的研究热点，因为它们可以精确递送至特定器官或组织以提高疗效并避免副作用。在此，我们对具有靶向功能的mRNA纳米药物的最新研究进展进行全面综述。首先详细描述mRNA及其载体。然后概述被动靶向、内源性靶向和主动靶向的机制，重点关注mRNA在体内递送过程中可能遇到的各种生物屏障。接下来，重点总结基于mRNA的器官靶向策略。最后，提及mRNA纳米药物在临床转化中的优势和挑战。本综述有望启发该领域的研究人员并推动mRNA靶向技术的进一步发展。